Recurrence: Clinical Trials

3,569 trials for Recurrence, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1448 completed, 567 unknown, 549 recruiting, 422 terminated. 1355 Phase 2, 1111 Phase 1, 498 Not applicable, 312 Phase 3, 125 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 21355Completed 523, Recruiting 213, Terminated 204, Unknown 176, Not yet recruiting 84, Active not recruiting 82, Withdrawn 66, Suspended 4, Enrolling by invitation 3
Phase 11111Completed 384, Terminated 208, Recruiting 207, Unknown 124, Active not recruiting 72, Not yet recruiting 60, Withdrawn 49, Suspended 4, Enrolling by invitation 3
Not applicable498Completed 230, Unknown 111, Recruiting 77, Not yet recruiting 25, Terminated 25, Active not recruiting 13, Withdrawn 11, Enrolling by invitation 5, Suspended 1
Phase 3312Completed 135, Unknown 47, Recruiting 43, Terminated 32, Active not recruiting 28, Not yet recruiting 15, Withdrawn 12
Phase 4125Completed 61, Unknown 28, Recruiting 13, Terminated 8, Not yet recruiting 7, Active not recruiting 4, Withdrawn 3, Enrolling by invitation 1
Early Phase 170Recruiting 21, Unknown 14, Not yet recruiting 11, Completed 8, Active not recruiting 6, Withdrawn 5, Terminated 4, Enrolling by invitation 1

Follow Recurrence: new trials by email Literature Review of Recurrence trials Research Report on Recurrence

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
YKST02 - Relapsed or Refractory Multiple Myeloma (RRMM)
Phase 2Not yet recruitingExcyte Biopharma Ltd642027-12-012026-11-06
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 1 / Phase 2Not yet recruitingClive Michelsen602027-07-012026-10-13
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
Dexbrompheniramine, Temozolomide - High Grade Glioma, Glioblastoma
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska412027-06-012026-10-05
Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.
CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies
Phase 1Not yet recruitingGUSTAVO SALGUERO122027-04-012026-10-20
Better Care Closer to Home: Enhancing Primary and Community Care
Path Active™, a smart insole system designed to reduce the risk of plantar ulceration in patients with diabetic foot disease - Diabetic Foot Disease, Recurrence
Not applicableNot yet recruitingUniversidad Complutense de Madrid842027-04-012026-11-03
Asciminib and Inotuzumab Ozogamicin for Relapsed or Refractory Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (R/R Ph+ B-ALL)
Asciminib, Inotuzumab ozogamicin - B-cell Acute Lymphoblastic Leukemia (B-ALL)
Phase 1RecruitingSunil G. Iyer452027-03-312026-11-13
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive
Phase 2Not yet recruitingMoein Amin202027-03-012026-08-19
Teclistamab In Waldenstrom's Macroglobulinemia
Teclistamab - Waldenstrom's Macroglobulinemia
Phase 2Not yet recruitingMassachusetts General Hospital242027-02-192026-09-01
RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT
LX-101 - Ewing Sarcoma
Phase 2Not yet recruitingM.D. Anderson Cancer Center1202027-02-012026-08-24
Analysis of the Performance of PSMA Emission Tomography in Patients With Prostate Cancer Treated With HIFU
Nuclear imaging (PSMA PET) with intravenous injection of a radiotracer one year after treatment (focal therapy) - Prostate Cancer - Recurrent, Prostate Cancer (Diagnosis)
Phase 4Not yet recruitingUniversity Hospital, Toulouse302027-02-012026-11-05
Phase 1 Dose Escalation Study of RXIM002 in Autoimmune Cytopenias
RXIM002 - Immune Thrombocytopenia (ITP)
Phase 1Not yet recruitingRiboX Therapeutics Ltd.272027-02-012026-10-28
Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL
Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia
Phase 1 / Phase 2Not yet recruitingDana-Farber Cancer Institute402027-01-132026-09-29
Zilovertamab Vedotin and Lenalidomide (ZiVLen) Therapy for Relapsed/Refractory Peripheral T-Cell Lymphoma
Zilovertamab vedotin Intravenous (IV) Infusion - 1.75 mg/kg, Lenalidomide - Peripheral T-Cell Lymphoma Refractory
Phase 2Not yet recruitingOlivia Newton-John Cancer Research Institute252027-01-012026-11-03
A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia
CAV - Acute Myeloid Leukemia (AML)
Phase 2Not yet recruitingUniversity of Rochester242026-12-312026-10-16
Aspirin and PAClitaxel in Head & Neck Squamous Cell Carcinoma
Aspirin, Paclitaxel - Head and Neck (HNSCC), Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Phase 2Not yet recruitingWashington University School of Medicine402026-12-312026-10-28
A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131
QLS4131, Pomalidomide Capsules, Bortezomib for Injection - Relapsed or Refractory Multiple Myeloma
Phase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.3002026-12-302026-11-12
IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
IASO206 injection - Autoimmune Hemolytic Anemia, Relapsed/Refractory
Phase 1Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, China182026-12-152026-11-05
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Phase 1 / Phase 2Not yet recruitingBeOne Medicines302026-12-012026-10-26
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
CAR-T cells, BCMA bispecific - Myeloma Multiple
Phase 1 / Phase 2Not yet recruitingCentre Hospitalier Universitaire de Saint Etienne442026-12-012026-10-09
Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38.
GNTbm-38 - Solid Tumor (Phase I), Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1Not yet recruitingGreat Novel Therapeutics Biotech & Medicals Corporation702026-12-012026-09-25

Showing 20 of 3569. Sign in to see all of them.

Narrower conditions

Multiple Myeloma (401)  ·  Leukemia, Myeloid, Acute (321)  ·  Lymphoma (284)  ·  Neoplasms (275)  ·  Neoplasm Metastasis (258)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (251)  ·  Lymphoma, Non-Hodgkin (244)  ·  Lymphoma, Large B-Cell, Diffuse (239)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (211)  ·  Leukemia (201)  ·  Burkitt Lymphoma (190)  ·  Hodgkin Disease (175)  ·  Lymphoma, Follicular (169)  ·  Lymphoma, Mantle-Cell (166)

Broader conditions

Pathological Conditions, Signs and Symptoms (3569)  ·  Pathologic Processes (3564)  ·  Disease Attributes (3563)  ·  Neoplasms (2245)  ·  Neoplasms by Histologic Type (1898)  ·  Hemic and Lymphatic Diseases (1438)  ·  Immune System Diseases (1295)  ·  Immunoproliferative Disorders (1149)  ·  Lymphoproliferative Disorders (1145)  ·  Neoplasms by Site (1001)  ·  Hematologic Diseases (968)  ·  Lymphatic Diseases (874)  ·  Cardiovascular Diseases (535)  ·  Neoplasms, Glandular and Epithelial (516)  ·  Vascular Diseases (500)

Interventions

Cyclophosphamide (170)  ·  Dexamethasone (151)  ·  Rituximab (101)  ·  fludarabine (97)  ·  Cytarabine (81)  ·  Lenalidomide (79)  ·  Gemcitabine (68)  ·  Bortezomib (67)  ·  fludarabine phosphate (65)  ·  venetoclax (60)  ·  Etoposide (59)  ·  pembrolizumab (55)  ·  pomalidomide (55)  ·  Carboplatin (50)  ·  Paclitaxel (50)

Sponsors

M.D. Anderson Cancer Center (62)  ·  Celgene (53)  ·  Novartis Pharmaceuticals (50)  ·  Memorial Sloan Kettering Cancer Center (48)  ·  National Cancer Institute (NCI) (39)  ·  Sun Yat-sen University (36)  ·  Fred Hutchinson Cancer Center (31)  ·  AbbVie (27)  ·  Assistance Publique - Hôpitaux de Paris (25)  ·  Amgen (24)  ·  Institute of Hematology & Blood Diseases Hospital, China (24)  ·  AstraZeneca (23)  ·  Pfizer (22)  ·  Dana-Farber Cancer Institute (20)  ·  H. Lee Moffitt Cancer Center and Research Institute (20)

Countries

United States (1455)  ·  China (688)  ·  France (389)  ·  Spain (304)  ·  Canada (295)  ·  Italy (290)  ·  Germany (285)  ·  United Kingdom (220)  ·  Australia (197)  ·  South Korea (173)  ·  Belgium (158)  ·  Netherlands (130)  ·  Japan (117)  ·  Poland (114)  ·  Taiwan (110)

Top investigators

Alison Moskowitz, MD (5)  ·  Brenda Sandmaier (5)

Results publications

PMID 34515338, PMID 32499241, PMID 41671463, PMID 26932146, PMID 30918100, PMID 31039052, PMID 31401903, PMID 32426039, PMID 35622074, PMID 22067384, PMID 22980441, PMID 23054212, PMID 23306310, PMID 24131282, PMID 24378877, PMID 24844673, PMID 26526385, PMID 26706103, PMID 27733070, PMID 28188133, PMID 28751099, PMID 28751558, PMID 28770420, PMID 29477379, PMID 29673108, PMID 31685558, PMID 32757523, PMID 33674274, PMID 33676197, PMID 33820822, PMID 34398557, PMID 34498507, PMID 34702811, PMID 35266417, PMID 35397664, PMID 35422096, PMID 35772429, PMID 35978286, PMID 36100310, PMID 36718018, PMID 37061656, PMID 37142273, PMID 37185961, PMID 37341961, PMID 37393120, PMID 37606897, PMID 38092009, PMID 38190117, PMID 38502198, PMID 39018512

NIH funding

2023 (49), 2015 (24), 2017 (20), 2018 (20), 2019 (19), 2016 (18), 2025 (16), 2009 (15), 2014 (15), P30CA015704 (13), 2008 (10), U01CA097452 (9), P30CA006973 (6), P30CA016672 (6), P30CA043703 (6)